Polycyclo Ring System Having The Six-membered Hetero Ring As One Of The Cyclos Patents (Class 546/18)
-
Publication number: 20110105546Abstract: Compounds according to formula (I): wherein R1, R2, R3, n and X are defined as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof, are useful for the modulation of CCR5 chemokine receptor activity. Additionally, compounds according to Formula III: wherein Z, R?1, and R?2 are defined as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof, are useful as intermediates for production of compounds that modulate CCR5 chemokine receptor activity.Type: ApplicationFiled: June 14, 2007Publication date: May 5, 2011Inventors: Christophe Moinet, Charles Blas, Monica Bubenik, Laval Chan Chun Kong, Marc Courchesne, Oswy Pereira, Réal Denis, Louis Vaillancourt, Constantin Yannopoulos
-
Publication number: 20110105470Abstract: The present invention provides novel tricyclic spiro-oxathiine naphthoquinone derivatives, a synthetic method for making the derivatives, and the use of the derivatives to induce cell death and/or to inhibit proliferation of cancer or precancerous cells. The naphthoquinone derivatives of the present invention are related to the compound known as ?-lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho(1,2-b)pyran-5,6-dione).Type: ApplicationFiled: January 11, 2011Publication date: May 5, 2011Applicant: ArQule, Inc.Inventors: Mark A. Ashwell, Manish Tandon, Jean-Marc Lapierre, Syed Ali, David Vensel, Chiang J. Li
-
Publication number: 20110105547Abstract: A compound, its pharmaceutically acceptable salt, a composition containing the same and method of treatment that can provide analgesia and/or reduce inflammation are disclosed. A contemplated compound has a structure that corresponds to Formula A, wherein G, W, Q, Z, D, E, F, K, Y, d, e, f, k, n, m, and circle B and all R groups are defined within.Type: ApplicationFiled: March 8, 2010Publication date: May 5, 2011Inventors: Lindsay Burns Barbier, Hoau-Yan Wang, Nan-Horng Lin, Andrei Blasko
-
Publication number: 20110092529Abstract: The present invention relates to a class of substituted triazoles of formula (I) with activity as oxytocin antagonists, uses thereof, processes for the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction, particularly premature ejaculation (P.E.).Type: ApplicationFiled: January 6, 2006Publication date: April 21, 2011Inventors: Alan Daniel Brown, Andrew Antony Calabrese, David Ellis
-
Patent number: 7928233Abstract: There are provided compounds of the formula or a pharmaceutically acceptable salt, ester or enantiomer thereof wherein W, X, Y, V, R1 and R2 are as described herein. The compounds have utility as antiproliferative agents, especially, as anticancer agents.Type: GrantFiled: January 12, 2010Date of Patent: April 19, 2011Assignee: Hoffmann-La Roche Inc.Inventors: Li Chen, Xingchun Han, Song Yang, Zhuming Zhang
-
Publication number: 20110077262Abstract: The invention relates to a compound of a general formula (I): wherein A represents a linking group; Ar1 represents a group formed from an aromatic ring; R1 and R2 each independently represent a hydrogen atom, a halogen atom, a cyano group, a C2-C6 alkenyl group, a C1-C6 alkoxy group, a halo-C1-C6 alkoxy group, a cyclo-C3-C6 alkyloxy group, a C2-C7 alkanoyl group, a halo-C2-C7 alkanoyl group, a C2-C7 alkoxycarbonyl group, a halo-C2-C7 alkoxycarbonyl group, a cyclo-C3-C6 alkyloxycarbonyl group, an aralkyloxycarbonyl group, a carbamoyl-C1-C6 alkoxy group, a carboxy-C2-C6 alkenyl group, or a group of -Q1-N(Ra)-Q2-Rb; a C1-C6 alkyl group optionally having substituent(s); an aryl or heterocyclic group optionally having substituent(s); or a C1-C6 alkyl group or a C2-C6 alkenyl group having the aryl or heterocyclic group; T and U each independently represent a nitrogen atom or a methine group; and V represents an oxygen atom, a sulfur atom or an imino group.Type: ApplicationFiled: June 29, 2009Publication date: March 31, 2011Inventors: Hideki Jona, Yoshihiro Shibata, Takeru Yamakawa
-
Patent number: 7906646Abstract: Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the ? opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other ? opioid receptor-mediated conditions.Type: GrantFiled: June 12, 2009Date of Patent: March 15, 2011Assignee: Adolor CorporationInventors: Roland E. Dolle, Bertrand Le Bourdonnec, Guo-Hua Chu
-
Publication number: 20110053970Abstract: Spirocyclic cyclohexane compounds useful in pharmaceutical compositions for use in the treatment of substance dependency.Type: ApplicationFiled: November 4, 2010Publication date: March 3, 2011Applicant: GRUENENTHAL GMBHInventors: Elmar FRIDERICHS, Babette-Yvonne Koegel, Klaus Linz
-
Patent number: 7892658Abstract: Disclosed is an organic light emitting device. The organic light emitting device comprises a first electrode, organic material layer(s) comprising a light emitting layer, and a second electrode. The first electrode, the organic material layer(s), and the second electrode form layered structure and at least one layer of the organic material layer(s) include the compound of Formula 1 or the compound of Formula 1 into which a thermosetting or photo-crosslinkable functional group is introduced.Type: GrantFiled: September 23, 2005Date of Patent: February 22, 2011Assignee: LG Chem, Ltd.Inventors: Seok Hee Yoon, Jae Min Moon, In Ho Hwang, Min Jeong Lee, Wook Dong Cho, Ji Eun Kim, Byung Sun Jeon
-
Patent number: 7893079Abstract: Compounds of formula I: (wherein variables A1, A2, A3, A4, m, n, J, Q, R4, Ea, Eb, Ec, R6, R7, Re, Rf, RPG and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.Type: GrantFiled: November 9, 2009Date of Patent: February 22, 2011Assignee: Merck Sharp & Dohme Corp.Inventors: Michael R. Wood, Steven N. Gallicchio, Harold G. Selnick, C. Blair Zartman, Ian M. Bell, Craig A. Stump
-
Publication number: 20110034455Abstract: This invention relates to novel compounds of the Formula (I*), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11?-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell.Type: ApplicationFiled: August 24, 2007Publication date: February 10, 2011Inventors: David A. Claremon, Suresh B. Singh, Colin M. Tice, Yuanjie Ye, Salvacion Cacatian, Wei He, Robert Simpson, Zhenrong Xu, Wei Zhao
-
Publication number: 20110034500Abstract: This invention is directed to spiroheterocyclic compounds of formula (I): wherein k, j, p, Q, R1, R3a, R3b, R3e, and R3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, that are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of using the compounds are also disclosed.Type: ApplicationFiled: August 12, 2010Publication date: February 10, 2011Applicant: Xenon Pharmaceuticals Inc.Inventors: Mikhail Chafeev, Sultan Chowdhury, Robert Fraser, Jianmin Fu, Rajender Kamboj, Shifeng Liu, Mehran Seid Bagherzadeh, Jianyu Sun, Serguei Sviridov
-
Patent number: 7872133Abstract: The present invention relates to the compound represented by formula (I) A-X—Y—Z—B??(I) (wherein A is a cyclic group which may have a substituent(s); X is a single bond or a spacer; Y is a single bond or a spacer; Z is a single bond or a spacer; B is a hydrocarbon group which may have a substituent(s) or a cyclic group which may have a substituent(s)), a salt thereof, a solvate thereof or a prodrug thereof. The compound represented by formula (I), a salt thereof, a solvate thereof or a prodrug thereof is useful for preventive and/or therapeutic agent for a disease caused by stress.Type: GrantFiled: June 22, 2004Date of Patent: January 18, 2011Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Kazuyuki Ohmoto, Masashi Kato, Takeshi Matsushita, Seishi Katsumata, Junichiro Manako
-
Patent number: 7868171Abstract: The present invention relates to selected glycidyl or carbonyl functional N-alkoxy-4,4-dioxy-polyalkyl-piperidine compounds forming an open chain or cyclic ketal structure, a polymerizable composition comprising a) at least one ethylenically unsaturated monomer and b) a glycidyl or carbonyl functional N-alkoxy-4,4-dioxy-polyalkyl-piperidine nitroxide initiator compound. Further aspects of the present invention are a process for polymerizing ethylenically unsaturated monomers and the use of glycidyl or carbonyl functional N-alkoxy-4,4-dioxy-polyalkyl-piperidine nitroxide initiators for radical polymerization.Type: GrantFiled: March 29, 2007Date of Patent: January 11, 2011Assignee: Ciba Specialty Chemicals Corp.Inventors: Francesco Fuso, Wiebke Wunderlich, Andreas Kramer, Jochen Fink
-
Publication number: 20110003808Abstract: This invention relates to novel octahydroquinolizines for treatment or prevention of diabetes mellitus and its complications, for treatment or prevention of hyperlipidemia, for treatment of diabetic dyslipidemia, for treatment or prevention of the metabolic syndrome, for treatment of diseases related to metabolic dysfunction, for treatment of obesity or obesity-related diseases. The invention also includes pharmaceutical compositions and kits comprising these compounds alone or in combination with other drugs or compounds aiming towards an improved treatment or prevention of the aforementioned diseases or syndromes in humans or animals.Type: ApplicationFiled: December 17, 2008Publication date: January 6, 2011Applicant: 55PHARMA DRUG DISCOVERY & DEVELOPMENT AGInventors: Immanuel Adorjan, Leonhardt Bauer, Klaus Frobel, Clemens Fuernsinn
-
Patent number: 7863449Abstract: The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.Type: GrantFiled: November 29, 2005Date of Patent: January 4, 2011Assignee: Vertex Pharmaceuticals IncorporatedInventors: Ioana Drutu, Dennis J. Hurley, Upul K. Bandarage, Daniele M. Bergeron, Paul S. Charifson, Robert J. Davies, Miguel Garcia-Guzman Blanco, Lewis R. Makings, Akiko Nakatani, Gabriel Raffai
-
Publication number: 20100329978Abstract: Compounds having the general formula II, III, or IV wherein R1 can be a radical of an optionally substituted C-4 to C-7 N-containing heterocycle or a radical of an optionally substituted cyclic or acyclic tertiary amine or isoindoline-1,3-dione: R2,3,4,5,6 can each independently be any one or combinations of the following moieties, cyano, nitro, acyl, alkyl, amido, azido, isothiocyanate, isocyanate, optionally substituted anilino, halogens, ethers, sulfonamides, thioacyl, nitro, aromatic, heterocyclic, olefinic, acetylene, deuterium, or tritium; Y can be either CH, CH2, O, S, OCH2, N—R, N—Ar, C—R, C—Ar; Z can be either H, O, S, S—R or NR.Type: ApplicationFiled: May 21, 2010Publication date: December 30, 2010Applicants: University of Mississippi, I'Universite catholique de LouvainInventors: Christopher R. McCurdy, Christophe Mesangeau, Rae Reiko Matsumoto, Jacques Henri Poupaert, Bonnie Ann Avery, Ahmed Hassan Amin Abdelazeem
-
Patent number: 7858790Abstract: The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.Type: GrantFiled: June 28, 2007Date of Patent: December 28, 2010Assignee: Vertex Pharmaceuticals IncorporatedInventors: Upul K. Bandarage, Jinwang Xu, Robert J. Davies, Paul S. Charifson, Rieko Arimoto
-
Publication number: 20100324024Abstract: The present invention is directed to compounds of formula (I) (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.Type: ApplicationFiled: February 3, 2009Publication date: December 23, 2010Applicant: Merck Sharp & Dohme Corp.Inventors: Scott D. Kuduk, Ronald K. Chang, Christina Ng Di Marco
-
Patent number: 7855202Abstract: The present disclosure relates to imidazopyridine derivatives of formula (I): The present disclosure also relates to a method for treating a subject afflicted with a pathological condition or disease susceptible to amelioration by antagonism of the A2B adenosine receptor.Type: GrantFiled: October 5, 2006Date of Patent: December 21, 2010Assignee: Laboratorios Almirall, S.A.Inventors: Bernat Vidal Juan, Silvia Fonquerna Pou, Paul Robert Eastwood, Jose Aiguade Bosch, Aranzazu Cardus Figueras, Ines Carranco Moruno, Jacob Gonzalez Rodriguez, Sergio Paredes Aparicio
-
Patent number: 7851464Abstract: Compounds of formula I: (wherein variables A1, A2, A3, A4, A5, A6, A7, E1, E2, E3, E4, E5, G1, G2, J and K are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.Type: GrantFiled: November 14, 2006Date of Patent: December 14, 2010Assignee: Merck Sharp & Dohme Corp.Inventors: Ian M. Bell, Harold G. Selnick, Michael R. Wood, Cory R. Theberge, Craig A. Stump, Steven N. Gallicchio, C. Blair Zartman
-
Patent number: 7842404Abstract: Disclosed is an organic light emitting device. The organic light emitting device comprises a first electrode, organic material layer(s) comprising a light emitting layer, and a second electrode. The first electrode, the organic material layer(s), and the second electrode form layered structure and at least one layer of the organic material layer(s) include the compound of Formula 1 or the compound of Formula 1 into which a thermosetting or photo-crosslinkable functional group is introduced.Type: GrantFiled: September 23, 2005Date of Patent: November 30, 2010Assignee: LG Chem, Ltd.Inventors: Wook Dong Cho, Ji Eun Kim, Byung Sun Jeon, Dong Seob Jeong, Seok Hee Yoon, Jae Min Moon
-
Patent number: 7842808Abstract: The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.Type: GrantFiled: January 5, 2007Date of Patent: November 30, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Prasad V. Chaturvedula, Ling Chen, Rita Civiello, Andrew P. Degnan, Gene M. Dubowchik, Xiaojun Han, Xiang Jun J. Jiang, Guanglin Luo, John E. Macor, Graham S. Poindexter, George O. Tora
-
Patent number: 7842803Abstract: Nicotinic acetylcholine receptor ligands of Formula I wherein X, n, R1 and R2 are as described in the specification, diastereoisomers, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing, and methods for using the same.Type: GrantFiled: May 17, 2007Date of Patent: November 30, 2010Assignee: AstraZeneca ABInventors: Hui-Fang Chang, Christopher Holmquist, Eifion Phillips, Timothy Piser, Thomas Simpson, Rebecca Urbanek, James Woods, Hui Xiong
-
Patent number: 7842405Abstract: Disclosed is an organic light emitting device. The organic light emitting device comprises a first electrode, organic material layer(s) comprising a light emitting layer, and a second electrode. The first electrode, the organic material layer(s), and the second electrode form layered structure and at least one layer of the organic material layer(s) include the compound of Formula 1 or the compound of Formula 1 into which a thermosetting or photo-crosslinkable functional group is introduced.Type: GrantFiled: September 23, 2005Date of Patent: November 30, 2010Assignee: LG Chem, Ltd.Inventors: Wook Dong Cho, Ji Eun Kim, Byung Sun Jeon, Jun Gi Jang, Seok Hee Yoon, Jae Min Moon
-
Patent number: 7838129Abstract: Disclosed is a novel compound which is capable of significantly improving a lifespan, efficiency, and electrochemical and thermal stabilities of an organic light emitting device, the production of the compound, and an organic light emitting device in which the compound is contained in an organic compound layer.Type: GrantFiled: September 23, 2005Date of Patent: November 23, 2010Assignee: LG Chem, Ltd.Inventors: Wook Dong Cho, Ji Eun Kim, Byung Sun Jeon, Seok Hee Yoon, Jae Min Moon
-
Patent number: 7838676Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein R1, W, B, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.Type: GrantFiled: November 14, 2006Date of Patent: November 23, 2010Assignee: Amgen Inc.Inventors: Qiufen Xue, Brian K. Albrecht, Denise Lyn Andersen, Michael Bartberger, James Brown, Ryan Brown, Stuart C. Chaffee, Yuan Cheng, Michael Croghan, Russell Graceffa, Scott Harried, Stephen Hitchcock, Randall Hungate, Ted Judd, Matthew Kaller, Charles Kreiman, Daniel La, Patricia Lopez, Craig Masse, Holger Monenschein, Thomas Nguyen, Thomas Nixey, Vinod F. Patel, Lewis Pennington, Matthew Weiss, Bryant Yang, Wenge Zhong
-
Publication number: 20100286396Abstract: The invention provides novel compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R7 are as described herein, compositions including the compounds and methods of preparing and using the compounds.Type: ApplicationFiled: April 30, 2010Publication date: November 11, 2010Inventors: Li Chen, Lichun Feng, Yongguo Li, Guolong Wu
-
Patent number: 7824779Abstract: Disclosed is an organic light emitting device. The organic light emitting device comprises a first electrode, organic material layer(s) comprising a light emitting layer, and a second electrode. The first electrode, the organic material layer(s), and the second electrode form layered structure and at least one layer of the organic material layer(s) include the compound of Formula 1 or the compound of Formula 1 into which a thermosetting or photo-crosslinkable functional group is introduced.Type: GrantFiled: September 23, 2005Date of Patent: November 2, 2010Assignee: LG Chem, Ltd.Inventors: Wook Dong Cho, Ji Eun Kim, Byung Sun Jeon, Jun Gi Jang, Seok Hee Yoon, Jae Min Moon
-
Patent number: 7820306Abstract: Disclosed is an organic light emitting device. The organic light emitting device comprises a first electrode, organic material layer(s) comprising a light emitting layer, and a second electrode. The first electrode, the organic material layer(s), and the second electrode form layered structure and at least one layer of the organic material layer(s) include the compound of Formula 1 or the compound of Formula 1 into which a thermosetting or photo-crosslinkable functional group is introduced.Type: GrantFiled: September 23, 2005Date of Patent: October 26, 2010Assignee: LG Chem, Ltd.Inventors: Seok Hee Yoon, Jae Min Moon, In Ho Hwang, Min Jeong Lee, Wook Dong Cho, Ji Eun Kim, Byung Sun Jeon
-
Patent number: 7816019Abstract: Disclosed is an organic light emitting device. The organic light emitting device comprises a first electrode, organic material layer(s) comprising a light emitting layer, and a second electrode. The first electrode, the organic material layer(s), and the second electrode form layered structure and at least one layer of the organic material layer(s) include the compound of Formula 1 or the compound of Formula 1 into which a thermosetting or photo-crosslinkable functional group is introduced.Type: GrantFiled: September 23, 2005Date of Patent: October 19, 2010Assignee: LG Chem, Ltd.Inventors: Wook Dong Cho, Ji Eun Kim, Byung Sun Jeon, Sang Young Jeon, Seok Hee Yoon, Jae Min Moon
-
Patent number: 7811682Abstract: Disclosed is a novel compound which is capable of significantly improving a lifespan, efficiency, and electrochemical and thermal stabilities of an organic light emitting device, the production of the compound, and an organic light emitting device in which the compound is contained in an organic compound layer.Type: GrantFiled: September 24, 2005Date of Patent: October 12, 2010Assignee: LG Chem, Ltd.Inventors: Wook Dong Cho, Ji Eun Kim, Byung Sun Jeon, Seok Hee Yoon, Jae Min Moon
-
Patent number: 7803807Abstract: The present invention relates to compounds of Formula (I) wherein A, B and C are independently methine, said methine being optionally substituted; D is nitrogen; T, U, V and W are independently methine or nitrogen, said methine being optionally substituted and least two of T, U, V and W are said methine groups; X is —N(SO2R4)—, N(COR5)— or —CO—; Y is C(R6)(R7)—, —O— or —N(R8) and a pharmaceutically acceptable salt, ester or N-oxide derivative thereof.Type: GrantFiled: October 26, 2009Date of Patent: September 28, 2010Assignee: Banyu Pharmaceutical Co., Ltd.Inventors: Norikazu Otake, Minoru Moriya, Yoshio Ogino, Kenji Matsuda, Yoshikazu Nagae, Akio Kanatani, Takehiro Fukami
-
Publication number: 20100240897Abstract: Spirocyclic cyclohexane compounds corresponding to formula I a method for producing them, pharmaceutical compositions containing them, and methods of using them.Type: ApplicationFiled: April 19, 2010Publication date: September 23, 2010Applicant: Gruenenthal GmbHInventors: Claudia Hinze, Otto Aulenbacher, Bernd Sundermann, Stefan Oberboersch, Elmar Friderichs, Werner Englberger, Babette-Yvonne Koegel, Klaus Linz, Hans Schick, Helmut Sonnenschein, Birgitta Henkel, Valerie Sarah Rose, Michael Jonathan Lipkin
-
Patent number: 7799441Abstract: Disclosed is an organic light emitting device. The organic light emitting device comprises a first electrode, organic material layer(s) comprising a light emitting layer, and a second electrode. The first electrode, the organic material layer(s), and the second electrode form layered structure and at least one layer of the organic material layer(s) include the compound of Formula 1 or the compound of Formula 1 into which a thermosetting or photo-crosslinkable functional group is introduced.Type: GrantFiled: September 23, 2005Date of Patent: September 21, 2010Assignee: LG Chem, Ltd.Inventors: Wook Dong Cho, Ji Eun Kim, Byung Sun Jeon, Min Jeong Lee, Seok Hee Yoon, Jae Min Moon
-
Patent number: 7785720Abstract: Disclosed is an organic light emitting device. The organic light emitting device comprises a first electrode, organic material layer(s) comprising a light emitting layer, and a second electrode. The first electrode, the organic material layer(s), and the second electrode form layered structure and at least one layer of the organic material layer(s) include the compound of Formula 1 or the compound of Formula 1 into which a thermosetting or photo-crosslinkable functional group is introduced.Type: GrantFiled: September 23, 2005Date of Patent: August 31, 2010Assignee: LG Chem, Ltd.Inventors: Wook Dong Cho, Ji Eun Kim, Byung Sun Jeon, Dong Seob Jeong, Seok Hee Yoon, Jae Min Moon
-
Publication number: 20100196269Abstract: Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the ?-opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other ?-opioid receptor-mediated diseases, disorders, and/or conditions.Type: ApplicationFiled: July 27, 2009Publication date: August 5, 2010Applicant: Adolor CorporationInventors: Roland E. Dolle, Bertrand Le Bourdonnec, Guo-Hua Chu
-
Publication number: 20100197716Abstract: The present invention provides novel ureas containing N-aryl or N-heteroaryl substituted heterocycles of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, D and W are as defined herein. These compounds are selective inhibitors of the human P2Y1 receptor which can be used as medicaments.Type: ApplicationFiled: April 16, 2010Publication date: August 5, 2010Inventors: Jennifer Qiao, Tammy C. Wang, James C. Sutton, Timur Gungor
-
Patent number: 7754732Abstract: The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.Type: GrantFiled: January 5, 2007Date of Patent: July 13, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Prasad V. Chaturvedula, Gene M. Dubowchik, Xiang Jun J. Jiang, John E. Macor, Graham S. Poindexter, Shikha Vig
-
Publication number: 20100168145Abstract: The patent application relates to new heterocyclic compounds of the general formula (I) in which A, R, R1, R2, X, Y, Z, n and p have the definitions elucidated in more detail in the description, to a process for preparing them and to the use of these compounds as medicaments, particularly as aldosterone synthase inhibitors.Type: ApplicationFiled: May 30, 2006Publication date: July 1, 2010Applicant: SPEEDEL EXPERIMENTA AGInventors: Peter Herold, Robert Mah, Vincenzo Tschinke, Aleksandar Stojanovic, Christiane Marti, Nathalie Jotterand, Christoph Schumacher, Michael Quirmbach
-
Publication number: 20100166819Abstract: The invention is related to compounds of formula (I) that can be used as antagonists of the TGF? family type I receptors, Alk5 and/or Alk4, compositions and methods of use. The compounds of formula (I) can be employed in the prevention and/or treatment of diseases such as fibrosis (e.g., renal fibrosis, pulmonary fibrosis, and hepatic fibrosis), progressive cancers, or other diseases for which reduction of TGF? family signaling activity is desirable.Type: ApplicationFiled: December 22, 2006Publication date: July 1, 2010Inventors: Wen-Cherng Lee, Lihong Sun, Michael Hoemann, Deqiang Niu, Dingxue Yan, Claudio Chuaqui, Russell Petter, Helen (Xiaomei) Feng
-
Publication number: 20100144774Abstract: The patent application relates to new heterocyclic compounds of the general formula (I), in which R, R1, R2, Q, T, n and p have the definitions elucidated in more detail in the description, to a process for preparing them and to the use of these compounds as medicaments, particularly as aldosterone synthase inhibitors.Type: ApplicationFiled: March 27, 2008Publication date: June 10, 2010Inventors: Peter Herold, Robert Mah, Stefan Stutz, Vincenzo Tschinke, Aleksandar Stojanovic, Nathalie Jotterand, Bibia Bennacer
-
Patent number: 7727999Abstract: The present invention relates to optionally substituted 1,3,8-triaza-spiro[4.5]decan-2-one compounds as monoamine receptor modulators; compositions comprising the same; methods of inhibiting an activity of a monoamine receptor with said compounds; methods of treating a disease condition associated with a monoamine receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.Type: GrantFiled: January 27, 2009Date of Patent: June 1, 2010Assignee: ACADIA Pharmaceuticals Inc.Inventor: Nathalie Schlienger
-
Publication number: 20100099684Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic ?7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.Type: ApplicationFiled: October 28, 2009Publication date: April 22, 2010Inventors: James H. Cook, II, Ivar M. McDonald, Dalton King, Richard E. Olson, Nenghui Wang, Christiana I. Iwuagwu, F. Christopher Zusi, John E. Macor
-
Patent number: 7700772Abstract: Compounds of Formula I and Formula II: (wherein n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R15, R16, R17, R18, R19, R24, R25, R26, R27, R28, R29, R30, R33, R34, R35, R36, R37, R38, A, j, k, m, n, X, Y and Z are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.Type: GrantFiled: February 8, 2005Date of Patent: April 20, 2010Assignee: Merck Sharp & Dohme Corp.Inventors: Lihu Yang, Alexander Pasternak, Sander G. Mills
-
Publication number: 20100081680Abstract: The current invention provides compounds having a structure according to Formulae 1, 2, 3, and 4: wherein the A-ring, B-ring, C-ring, m, n, R25, R50, and R51 are as described in the specification. The invention also provides pharmaceutical compositions comprising compounds of Formulae 1, 2, 3, and 4, as well as methods of treating cognitive disorders, such as Alzheimer's disease. The invention further provides intermediates useful in preparing the compounds of Formulae 1, 2, 3, and 4.Type: ApplicationFiled: September 4, 2009Publication date: April 1, 2010Inventors: Andrei W. Konradi, Xiaocong Michael Ye, Simeon Bowers, Albert W. Garofalo, Danielle L. Aubele, Darren Dressen, Raymond Ng, Gary Probst, Christopher M. Semko, Minghua Sun, Anh P. Truong, Michael S. Dappen
-
Publication number: 20100076004Abstract: The present invention is directed to bicyclic spiropiperidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.Type: ApplicationFiled: December 28, 2007Publication date: March 25, 2010Inventors: Shaun R. Stauffer, Samuel L. Graham
-
Publication number: 20100066241Abstract: The present invention relates to novel organic electroluminescent compounds, and organic electroluminescent devices comprising the same as electroluminescent material. Specifically, the organic electroluminescent compounds according to the invention are characterized in that they are represented by Chemical Formula (1): wherein, L1 is a substituent selected from the following structures; A and B independently represent a chemical bond, or a substituent selected from the following structures; m and n independently represent an integer from 0 to 4; provided that, if represents both X1 and X2 represent NR33, and both Y1 and Y2 represent a chemical bond, then R33 does not represent hydrogen or (C1-C5)alkyl. The organic electroluminescent compounds according to the invention exhibit high luminous efficiency in blue color and excellent life property of material, so that an OLED having very good operation life can be prepared therefrom.Type: ApplicationFiled: June 23, 2009Publication date: March 18, 2010Applicant: Gracel Display Inc.Inventors: Young Jun Cho, Hyuck Joo Kwon, Bong Ok Kim, Sung Min Kim, Seung Soo Yoon
-
Publication number: 20100069380Abstract: Provided herein are compounds that modulate the activity of a bacterial peptidyl tRNA hydrolase, including compositions and dosage forms comprising the compounds. Further provided herein are methods for screening and identifying compounds that modulate the activity of a bacterial peptidyl tRNA hydrolase. In particular, provided herein are assays for the identification of compounds that inhibit or reduce the activity of a bacterial peptidyl tRNA hydrolase. The methods provided herein provide a simple, sensitive assay for high-throughput screening of libraries of compounds to identify pharmaceutical leads useful for preventing, treating, and managing a bacterial infection or one or more symptoms thereof. Further provided herein are methods for preventing or inhibiting bacterial proliferation as well as methods for preventing, treating, and/or managing a bacterial infection using such compounds and compositions.Type: ApplicationFiled: September 21, 2007Publication date: March 18, 2010Inventors: Soongyu Choi, Arthur Branstrom, Scott A. Gothe, Richard Lipman, Tamil Arasu, Richard G. Wilde
-
Publication number: 20100048600Abstract: The present invention relates to a compound of the formula (I): (wherein A, B, C and D are independently nitrogen or optionally substituted methine; E is nitrogen, methine or hydroxy substituted methine; n is 0 or 1; T, U, V and W are independently nitrogen or optionally substituted methine; X is —N(SO2R4)—, —N(COR5)— or —CO—; Y is —C(R6)(R7)—, —O— or —N(R8)—, provided that the compound (I) when E is nitrogen, n is 0, X is —CO—, and Y is —O— is excluded) and the like, which are useful as an agent for the treatment of various diseases related to NPY, for example cardiovascular disorders such as angina, acute or congestive heart failure, myocardial infarction, hypertension, nephropathy, electrolyte abnormality, vasospasm, arteriosclerosis, etc., central nervous system disorders such as bulimia, depression, anxiety, seizure, epilepsy, dementia, pain, alcoholism, drug withdrawal, circadian rhythm disorders, schizophrenia, memory impairment, sleep disorders, cognitive impairment, etc.Type: ApplicationFiled: October 26, 2009Publication date: February 25, 2010Inventors: NORIKAZU OTAKE, Minoru Moriya, Yoshio Ogino, Kenji Matsuda, Yoshikazu Nagae, Akio Kanatani, Takehiro Fukami